Preclinical and Clinical Properties of Bezlotoxumab (ZINPLAVA® 25 Mg/mL Concentrate for Solution for Infusion), Novel Therapeutic Agent for Clostridium Difficile Infection

Folia Pharmacologica Japonica - Japan
doi 10.1254/fpj.152.39
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Japanese Pharmacological Society

Related search

Pharmacological and Clinical Profile of Dexrazoxane (SAVENE® Intravenous Infusion 500 Mg), a Therapeutic Agent for Anthracycline Extravasation

Folia Pharmacologica Japonica
Pharmacology
2015English

An Agent-Based Simulation Model for Clostridium Difficile Infection Control

Medical Decision Making
Health Policy
2014English

Pin35 - Cost-Effectiveness of Bezlotoxumab for the Prevention of Recurrence of Clostridium Difficile Infection in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Comment on "A Small-Molecule Antivirulence Agent for Treating Clostridium Difficile Infection"

Science Translational Medicine
Medicine
2016English

Diagnosis of Clostridium Difficile Infection: An Ongoing Conundrum for Clinicians and for Clinical Laboratories

Clinical Microbiology Reviews
ImmunologyEnvironmentalPublic HealthMicrobiologyMicrobiology EpidemiologyInfectious DiseasesOccupational Health
2013English

Economics Analysis of Diagnostic Methods for Clostridium Difficile Infection

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Clostridium Difficile Infection

Nature Reviews Disease Primers
Medicine
2016English

Clostridium Difficile Infection

Nature Reviews Disease Primers
Medicine
2016English

Clostridium Difficile Infection

Inflammatory Bowel Diseases
AllergyImmunologyGastroenterology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy